C
URRENT TREATMENT OPTIONS in patients with acromegaly due to a GH-secreting pituitary adenoma are surgery, medical therapy, and radiotherapy. As medical therapy, stable somatostatin (SRIF) analogs, such as octreotide (OCT) and the sustained-release depot formulations Sandostatin-LAR and SR-lanreotide are widely used, both as primary or secondary therapy (1) . Treatment with this generation of octapeptide SRIF analogs results in clinical and biochemical control, i.e. normalization of circulating GH and IGF-I levels, in approximately two thirds of the acromegalic patients (1) . The successful medical treatment of acromegaly with octapeptide SRIF analogs is due to the expression of high-affinity (density) SRIF receptors on the adenoma cells, mainly somatostatin receptor (sst) 2 , which is one of the five known SRIF receptor subtypes, sst [1] [2] [3] [4] [5] , and the selective highaffinity binding of these analogs to the sst 2 subtype (2). The molecular basis for the clinical experience that one third of patients with acromegaly are not adequately controlled by treatment with octapeptide SRIF analogs is probably formed by a variable expression of sst [1] [2] [3] [4] [5] in the adenomas of these patients (3) (4) (5) (6) (7) (8) (9) . Several groups have demonstrated that sst 2 and sst 5 receptors are the most important sst involved in the regulation of GH secretion (2, 9) . Using sst selective SRIF analogs, it was shown that, in adenomas that were poorly responsive to the sst 2 selective agonists OCT and lanreotide, sst 5 selective or sst 2 -sst 5 bispecific compounds were able to suppress GH release more potently (10, 11) .
These observations initiated the development of novel stable SRIF analogs with a more universal sst binding profile. One of these new compounds, SOM230, was recently shown to reduce circulating IGF-I levels in rats by 75% after 126 d of continuous infusion. This effect was significantly more potent, compared with OCT, which suppressed IGF-I release under the same experimental condition by only 28% (12) . In rats, the terminal elimination half-life was 23 h, which is approximately 11 times longer, compared with OCT (12) . Finally, in both cynomolgus monkeys and beagle dogs, infusion of SOM230, and to a much lesser extent OCT (SMS 201-995), lowered IGF-I levels potently (13) . Compared with OCT, SOM230 has a 30, 5, and 40 times higher binding affinity to sst 1 , sst 3 , and sst 5 receptors, respectively, and 2.5 times lower affinity to sst 2 (Ref. 12 and Table 1 ). This universal binding profile of SOM230 to sst, in combination with the importance of sst 2 and sst 5 receptors in regulating GH secretion by pituitary adenoma cells, was the rationale for the present study to evaluate, for the first time, the effects of SOM230, OCT, and the native SRIF molecule SRIF-14 on hormone secretion by human GH-secreting pituitary adenomas. Moreover, recent evidence suggests that sst 5 receptors are also involved in the regulation of prolactin (PRL) secretion by human prolactinoma cells (11, 14) . Therefore, we compared the effects of OCT and SOM230 on PRL secretion by primary cultures of human prolactinomas. A correlation is made with the sst subtype expression patterns in the adenoma cells.
Patients and Methods Patients
Pituitary tumor samples were obtained by transsphenoidal operation from nine patients with GH-secreting pituitary adenomas and from three patients with prolactinomas as described in detail previously (15) . Diagnosis was made on the basis of clinical and biochemical characteristics of the patients, in combination with (immuno)histochemistry of the tumor samples (Table 2 ). All patients gave their informed consent for the use of tumor material for research purposes. Directly after obtaining the tissue, a piece of tissue was snap frozen on dry ice and stored at Ϫ80 C until analysis. The remaining tissue was used for cell culture.
To evaluate in vivo responsiveness to OCT, patients received at 0900 h a single sc injection of 100 g OCT. Blood samples were collected 30 min before and 1 min before, and hourly until 0800 h after sc injection. At the same time points, blood samples were taken at a control day. The effect of OCT on circulating GH levels was determined by calculating the mean GH suppression between 2 and 8 h after sc injection, compared with the same period of time on a control day.
Quantitative PCR
Quantitative PCR was performed as described previously (16) . Briefly, poly A ϩ mRNA was isolated using Dynabeads Oligo (dT) 25 (Dynal AS, Oslo, Norway) from freshly isolated pituitary adenoma cell pellets containing 0.5-1.0 ϫ 10 6 adenoma cells. Analysis of sst subtype mRNA levels in both tissue or freshly isolated cell pellets (n ϭ 4) yielded comparable results (data not shown). cDNA was synthesized using the poly A ϩ mRNA, which was eluted from the beads in 40 l H 2 O for 10 min at 65 C, using Oligo (dT) [12] [13] [14] [15] [16] [17] [18] primer (Invitrogen, Breda, The Netherlands). One twentieth of the cDNA library was used for quantification of sst subtype mRNA levels. A quantitative PCR was performed by TaqMan Gold nuclease assay (Perkin-Elmer Corp., Foster City, CA) and the ABI PRISM 7700 sequence detection system (Perkin-Elmer) for real-time amplifications, according to manufacturer's protocol. The assay was performed using 15 l TaqMan Universal PCR master mix (Applied Biosystems, Capelle aan de ijssel, The Netherlands), 500 nm forward primer, 500 nm reverse primer, 100 nm probe and 10 l cDNA template, in a total reaction volume of 25 l. The reactions were carried out in a ABI 7700 sequence detector (Perkin-Elmer, Groningen, The Netherlands). After an initial heating at 95 C for 8 min, samples were subjected to 40 cycles of denaturation at 95 C for 15 sec and annealing for 1 min at 60 C. The primer and probe sequences that were used are indicated below. The detection of hypoxanthine-phosphoribosyl-transferase (hprt) mRNA served as a control and was used for normalization of the sst subtype mRNA levels.
The primer sequences that were used included the following: hprt forward, 5Ј-TGCTTTCCTTGGTCAGGCAGTAT-3Ј; hprt reverse, 5Ј-TCAAATCCAACAAAGTCTGGCTTATATC-3Ј; sst 1 forward, 5Ј-TGAG-TCAGCTGTCGGTCATC-3Ј; sst 1 reverse, 5Ј-ACACTGTAGGCACG-GCTCTT-3Ј; sst 2 forward, 5Ј-TCGGCCAAGTGGAGGAGAC-3Ј; sst 2 reverse, 5Ј-AGAGACTCCCCACACAGCCA-3Ј; sst 3 forward, 5Ј-CT-GGGTAACTCGCTGGTCATCTA-3Ј; sst 3 reverse, 5Ј-AGCGCCAGGT-TGAGGATGTA-3Ј; sst 5 forward, 5Ј-CATCCTCTCCTACGCCAACAG-3Ј; and sst 5 reverse, 5Ј-GGAAGCTCTGGCGGAAGTT-3Ј.
The probe sequences that were used included the following: hprt, 5Ј-FAM-CAAGCTTGCGACCTTGACCATCTTTGGA-TAMRA-3Ј; sst 1 , 5Ј-FAM-ACAGCTGCGCCAACCCCATC-TAMRA-3Ј; sst 2 , 5Ј-FAM-CCGGACGGCCAAGATGATCACC-TAMRA-3Ј; sst 3 , 5Ј-FAM-CGGC-CAGCCCTTCAGTCACCAAC-TAMRA-3Ј; and sst 5 , 5Ј-FAM-CCCGT-CCTCTACGGCTTCCTCTCTGA-TAMRA-3Ј.
Primers and probes were purchased from Biosource (Nivelles, Belgium).
The relative amount of sst subtype mRNA was determined using a standard curve generated from known amounts of human genomic DNA. For determination of the amount of hprt mRNA, a standard curve was generated of a pool of cDNAs from a human cell line known to express hprt. The linear range of amplification ranged between 4 log dilutions of genomic DNA or cDNA, respectively. The relative amount of sst subtype mRNA was calculated relative to the amount of hprt mRNA and is given in arbitrary units. Each sample was assayed in duplicate.
Cell dispersion and cell culture
Single-cell suspensions of the pituitary adenoma tissues were prepared by enzymatic dissociation with dispase as described in detail previously (15) . For short-term incubation of monolayer cultures, the dissociated cells were plated in 48-well plates (Corning, Cambridge, MA) at a density of 10 5 cells per well per 1-ml culture medium. After 3-4 d the medium was changed and 72-h incubations without or with test substances were initiated. At the end of the incubation, the medium was removed and centrifuged for 5 min at 600 ϫ g. The supernatant was collected and stored at Ϫ20 C until analysis. The choice for a 72-h incubation was made on the basis of previous studies, in which we demonstrated that exposure of GH-secreting pituitary adenoma cells for 4 -96 h to octreotide showed a variable, but in all instances during longer incubations statistically significant inhibition of GH release, which paralleled the sensitivity of GH secretion to octreotide in vivo (17) . For long-term incubation studies in Transwells (18), the isolated tumor cells were plated in Transwell-COL membranes (Corning) at a density of 10 5 cells/well. The Transwells were then placed into multiwell plates (24-well, Corning) containing 1 ml culture medium. After 72 h the Transwells were transferred to wells containing fresh medium (without or with test substances). Every 3-4 d the cells were placed into fresh medium and the incubation media were collected and stored at Ϫ20 C until determination of hormone concentrations.
The cells were cultured at 37 C in a CO 2 incubator. The culture medium consisted of MEM supplemented with nonessential amino acids, sodium pyruvate (1 mmol/liter), 10% fetal calf serum, penicillin (1 ϫ 10 5 U/liter), fungizone (0.5 mg/liter), l-glutamine (2 mmol/liter), and sodium bicarbonate (2.2 g/liter, pH 7.6). Media and supplements were obtained from Gibco Bio-cult Europe (Invitrogen, Breda, The Netherlands).
Unfortunately, generally not enough tumor material was obtained to test for each tumor the dose dependency of effects for the indicated drugs.
Hormone determinations
Human GH and PRL concentrations in the media and cell extracts were determined by a nonisotopic, automatic chemiluminescence immunoassay system (Immulite; Diagnostic Products Corp. Inc., Los Angeles, CA). Intra-and interassay coefficients of variation for GH and PRL were 6.0 and 5.7% and 6.2 and 6.4%, respectively. ACTH, LH, and FSH concentrations in the culture media were determined as well to exclude the presence of contaminating normal pituitary cells in the cultures. Human ACTH, LH, and FSH concentrations were determined by a nonisotopic, automatic chemiluminescence immunoassay system (Immulite, Diagnostic Products Corp. Inc.). Intra-and interassay coefficients of variation for ACTH, LH, and FSH were 5.6, 5.7, and 6.4% and 7.8, 12.3, and 7.5%, respectively. Except for the expected hormones GH and PRL, none of the other hormones were detectable (not shown).
Test substances
OCT (Sandostatin) and bromocriptine were obtained from Novartis Pharma A.G. (Basel, Switzerland). SOM230 was provided by Novartis Pharma A.G. Somatostatin-14 (SRIF-14) was purchased from Sigma Chemical Co. (St. Louis, MO).
Statistical analysis of the data
All data on hormone release are expressed in mean Ϯ se, n ϭ 4 wells per treatment group. All data were analyzed by ANOVA to determine overall differences between treatment groups. When significant differences were found by ANOVA, a multiple comparison between treatment groups was made using the Newman-Keuls test. Correlation analysis was done by the use of the Spearman's rank correlation test. Calculation of IC 50 values for inhibition of hormone release were made using GraphPad Prism (San Diego, CA). 1 , sst 2 , sst 3 , and sst 5 mRNA expression levels in GH-secreting pituitary adenomas. Values are expressed as the number of copies of the respective sst mRNAs, relative to the number of copies of hprt. nd, Not detectable. Note the differences in the scale of the y-axis between sst 1 , sst 2 , and sst 3 mRNA levels on the one hand, and the higher sst 5 mRNA levels on the other hand. The relative amount of sst subtype mRNA was calculated relative to the amount of hprt mRNA and is given in arbitrary units.
FIG. 1. Relative sst

Results
Sst subtype mRNA expression and correlation with in vivo GH suppression by octreotide
In seven of nine GH-secreting pituitary adenoma samples the sst subtype mRNA expression pattern was determined. Figure 1 shows that two adenomas expressed sst 1 mRNA, three adenomas expressed sst 3 mRNA and that all adenomas expressed sst 2 and sst 5 mRNAs. Expression of sst mRNAs was variable between adenoma samples. The difference between the lowest and the highest level measured, amounted to 7-, 8-, 3-, and 5-fold for sst 1 , sst 2 , sst 3 , and sst 5 , respectively. The sst subtype mRNA levels showed no statistical correlation (data not shown). The mean percentage in vivo GH suppression (range ϩ18 and Ϫ91% suppression) between 2 and 8 h after the administration of a single sc dose of 100 g OCT (patients 1, 2, 3, 5, 6, and 7) was positively correlated with sst 2 mRNA expression levels (Fig. 2, left panel) but not with sst 5 mRNA levels (Fig. 2, right panel) .
Effects of SS analogs on GH secretion
In most GH-secreting pituitary adenomas, the effect of 10 nm OCT, SOM230, or SRIF-14 on GH release was evaluated in parallel in vitro. Figure 3 shows that GH release was significantly suppressed by OCT in seven of nine cultures, by SOM230 in eight of nine cultures and by SRIF-14 in six of six cultures. In the majority of the adenomas, the percentage suppression using a maximally active concentration of the three compounds, was comparable. Only the adenoma cells of patient 7 showed a dissociated response to OCT on the one hand and to SOM230 and SRIF-14 on the other hand. In this adenoma culture, GH release was not inhibited by OCT, whereas both SOM230 and SRIF-14 induced a statistically significant suppression of GH release. In the respective patient, OCT (100 g sc) did not suppress GH concentrations as well. As seen in Fig. 3 , the response in terms of GH suppression was variable between the individual adenoma cultures. This variable responsiveness to OCT and SOM230 correlated well with the sst 2 mRNA expression levels in the adenoma cells of the respective patients (Fig. 4, upper panel) . Comparable to the patients responsiveness to OCT, sst 5 mRNA expression showed no statistically significant correlation with the percentage of GH suppression by 10 nm OCT.
Interestingly, the effects of 10 nm SOM230, which shows a more universal binding profile for sst receptors, including high-affinity binding to sst 5 , also showed no correlation with sst 5 mRNA expression levels. This is demonstrated in Fig. 4  (lower panel) .
In several adenoma cultures, the dose-response relationship of the inhibitory effects of OCT, SOM230, and SRIF-14 could be evaluated. Figure 5 (right panel) shows the effects of the three compounds on GH release by the adenoma cells of patient 7, which did not respond to OCT. The adenoma cells of this patient had the lowest sst 2 mRNA levels of all cases studied (Fig. 1, upper right panel) . As shown, GH release by the cells of this patient was inhibited in a dose-dependent manner by both SOM230 and SRIF-14. The IC 50 values for the inhibition of GH release were 0.5 and 0.6 nm for SOM230 and SRIF-14, respectively. In the other adenoma cultures, both OCT and SRIF-14 were slightly more efficacious, in terms of IC 50 values, compared with SOM230. Figure 5 
Effects of somatostatin (SS) analogs on PRL secretion
Because previous studies demonstrated the involvement of sst 5 receptors in regulating PRL release, we also compared the effects of OCT and SOM230 on PRL release. Five adenoma cultures cosecreted PRL as well. OCT (10 nm) and SOM230 (10 nm) significantly inhibited PRL release in four of five and five of five cultures, respectively (Fig. 6) . The percentage suppression was between 16 and 66% for OCT and between 38 and 74% for SOM230, indicating its higher efficacy. In four of five cultures (no. 1, 3, 8, and 9), SOM230 was significantly more potent with regard to its maximal suppressive effect on PRL release, when compared with OCT (P Ͻ 0.01).
In addition to mixed GH/PRL-secreting pituitary adenomas, we also compared the effects of OCT and SOM230 on PRL release in three primary human prolactinoma cultures (no. 10, 11, and 12) ( Table 2 ). Figure 7 shows that prolactinoma no.10 selectively expresses a high level of sst 5 mRNA, whereas prolactinoma 11 expressed sst 1 mRNA but very low sst 5 mRNA. In agreement with the low affinity of OCT for sst 5 and the very high affinity of SOM230 for this sst, 10 nm OCT did not significantly inhibit PRL release by the two prolactinoma cultures, whereas 10 nm SOM230 potently suppressed (Ϫ49%) PRL release by cells of adenoma 10 (high sst 5 ) and slightly (Ϫ23%) by cells of prolactinoma no.11 (low sst 5 ). Both adenoma cultures showed high sensitivity to 10 nm of the dopamine agonist bromocriptine (Ϫ73 and Ϫ89% inhibition in cultures 10 and 11, respectively). In one prolactinoma culture (no. 12) the long-term in vitro effects of OCT, SOM230, and bromocriptine were studied. Figure 8 shows that both SOM230 (10 nm) and bromocriptine (10 nm) suppressed PRL release by approximately 90% after 9 d of continuous incubation with the compounds. In this particular adenoma, OCT was only slightly effective (Ϫ30% after 9 d). Unfortunately, not enough tissue was obtained from this patient to study the sst subtype expression pattern.
Discussion
SRIF receptor expression on GH-secreting pituitary adenomas forms the basis for successful treatment of acromegalic patients using sst 2 -selective octapeptide SRIF-analogs (19, 20) . Recent in vitro studies have demonstrated that both sst 2 and sst 5 receptors are involved in the regulation of GH release by normal human fetal anterior pituitary cells and GH-secreting pituitary adenoma cells (2, 9, 11) . In addition, evidence exists that sst 5 exclusively regulates PRL secretion from human prolactinoma cells (11, 14) . Moreover, BIM-23244, a SRIF analog with high-affinity binding to sst 2 and sst 5 receptors, was shown to achieve a better suppression of GH secretion by cultured GH-secreting pituitary adenomas that were partially responsive to OCT, suggesting that such bispecific SS analogs could achieve a better control of GH secretion in a larger number of acromegalic patients (10) . The recent observation that sst subtypes may form homo-and heterodimers, resulting in receptors with enhanced binding affinity and modified functional properties (21, 22) , may form one of the explanations for the enhanced efficacy of bispecific compounds such as BIM-23244. In addition, an sst 2 antagonist was shown to inhibit the GH suppressing action of sst 2 /sst 5 biselective agonists in human fetal pituitary cells, supporting the concept of functional interaction between sst 2 and sst 5 receptors in the regulation of GH secretion (23). Recently a novel stable SRIF analog, with a more universal binding profile and high-affinity binding to sst 1 , sst 2 , sst 3 , and sst 5 , was introduced (12, 13) . This SRIF analog, SOM230, was shown to be significantly more potent in lowering IGF-I levels in rats, compared with the sst 2 -preferring analog OCT (12) . SOM230 has a favorable elimination half-life of 23 h (12), suggesting that this analog may be suitable for clinical application as well (24) . On the basis of the involvement of sst 2 /sst 5 receptors in regulating GH secretion and sst 5 receptors in regulating PRL secretion, we compared in the present study the efficacy of SOM230 in the regulation of GH and PRL release by primary cultures of human pituitary adenoma cells.
In agreement with previous studies (3-10), we found a variable expression of sst mRNAs, predominantly sst 2 and sst 5 , in our series of GH-secreting pituitary adenomas. Only selected cases expressed sst 1 and sst 3 mRNAs, suggesting that these sst subtypes are probably of less importance in this type of pituitary adenoma. Moreover, in most adenomas, sst 5 expression levels were relatively higher, compared with sst 2 mRNA levels. On the other hand, the preoperative response of acromegalic patients to a single sc administration of 100 g OCT was positively correlated with the sst 2 mRNA, but not with sst 5 mRNA levels, in the pituitary adenomas of the patients obtained via transsphenoidal surgery. These data demonstrate that the sst 2 subtype is clearly the predominant receptor determining in vivo responsiveness to OCT in acromegalic patients.
In agreement with previous observations (10), sst 2 mRNA levels were positively correlated with the in vitro GH suppression by this sst 2 selective SRIF analog as well. Surprisingly, although SOM230 shows a very high affinity for sst 5 receptors, no significant correlation was found between the in vitro GH suppression by a maximally active concentration of SOM230 and sst 5 mRNA levels, whereas a positive correlation was found between the effects of SOM230 and sst 2 mRNA levels. Although these data were unexpected, a previous study by Jaquet et al. (9) in fact already made the same observation using SRIF-14. In this study, sst 2 mRNA but not sst 5 mRNA levels in GH-secreting pituitary adenomas showed a positive correlation with in vitro GH suppression by 1 nmol/liter SRIF-14.
As suggested by Jaquet et al. (9) , it is not known yet whether the observed sst mRNA levels directly correlate with sst protein levels. The importance of the sst 2 subtype in regulating GH secretion by the majority of human GHsecreting pituitary adenomas is also evident by our observation that the potency of OCT in terms of IC 50 values measured for the inhibition of GH release are slightly higher, compared with SOM230. Nevertheless, SOM230 shows a high efficacy to inhibit GH release, with an IC 50 value in the low nanomolar range. In 89% of the cultures SOM230 significantly inhibited GH release. In this respect, OCT is slightly less efficacious, with a significant GH-suppressive effect in seven of nine cultures (78%). In one OCT-resistant culture, SOM230 inhibited GH release with an IC 50 value comparable with that of SRIF-14 (IC 50 , 0.5 and 0.6 nm, respectively), confirming the importance of the sst 5 receptor subtype in mediating GH release, when sst 2 levels are low. However, although SOM230 has a slightly lower potency (IC 50 ) for the inhibition of GH release in most cases, compared with OCT, its efficacy is higher, compared with OCT, in terms of the number of responders. Therefore, in addition to the sst 2 /sst 5 bispecific compound BIM-23244, SOM230 also has the potential to achieve better control of GH hypersecretion in a larger number of acromegalic patients. Moreover, the very favorable elimination half-life of SOM230 (12) makes this compound an interesting candidate for clinical application as well.
Apart from regulating GH secretion, sst 5 receptors play a regulatory role in normal and tumoral PRL secretion as well (2, 11, 14) . A significant proportion of GH-secreting pituitary adenomas contain GH-and PRL-expressing cells, either as individual cells expressing GH or PRL or as mammosomatotroph cells expressing GH and PRL in the same cells (25) . In agreement with these data, we observed cosecretion of GH and PRL in 56% of the cultures and showed that SOM230 has a potent inhibitory effect on PRL secretion in mixed GH-PRLsecreting pituitary adenomas and prolactinomas. In four of five mixed GH-PRL-secreting pituitary adenomas, SOM230 was significantly more potent, compared with OCT, in its maximal suppressive effect on PRL secretion. Recently it was shown that activation of sst 1 by the sst 1 -selective agonist BIM-23296 caused a dose-dependent inhibitory effect in the nanomolar range on GH and PRL secretion by GH-secreting pituitary adenomas. In addition to lowering GH and PRL secretion, this SS-analog induced a decrease in cell viability as well (26) . In our series we found that two of seven adenomas expressed sst 1 . In selected cases, therefore, sst 1 may play a regulatory role on GH-secreting pituitary adenoma cell function as well.
In three dopamine (DA) agonist-sensitive prolactinomas, SOM230 was significantly more potent than OCT in lowering PRL secretion. In two of the prolactinomas, there was a clear relationship between the expression of sst 5 mRNA in the adenoma cells and the percentage inhibition of PRL secretion by SOM230. In one prolactinoma culture, which expressed high levels of sst 5 mRNA and no other sst mRNAs, PRL secretion was reduced to the same extent as that induced by bromocriptine. One other prolactinoma, which showed a significantly lower responsiveness to SOM230, had very low sst 5 mRNA levels. The lower potency of OCT in reducing PRL secretion by prolactinomas seems related to the very low sst 2 levels, as was demonstrated in a series of 10 prolactinomas by Jaquet et al. (14) . These data further underline the role of sst 5 in mediating its suppressive effect on PRL secretion. However, the potential clinical importance of these findings should be considered in view of the very high proportion of patients with prolactinomas responding to DA agonist treatment with a normalization of PRL levels and tumor shrinkage (27, 28) . In addition, Jaquet et al. (14) previously showed that the effects of sst 5 selective compounds on prolactinoma cells are superimposable at higher concentration to those of the DA agonists, but not additive, particularly in adenomas resistant to dopaminergic suppression of PRL release.
Whereas sst 5 receptors may mediate antiproliferative effects (29) , the role of this receptor in the control of pituitary adenoma cell proliferation is unclear. Indirect evidence for a role of sst 5 in the regulation of human GH-secreting pituitary adenoma cell proliferation was obtained from the observation of a germ line mutation (Arg240Trp) in genomic DNA from pituitary adenoma and peripheral blood mononuclear cells of an acromegalic patient resistant to SRIF analog treatment and a higher proliferation rate of cells overexpressing this mutant sst 5 receptor, compared with cells expressing wild-type sst 5 (30) . Whether activation of sst 5 receptors expressed on human GH-secreting pituitary adenomas and prolactinomas also mediates an antiproliferative effect in these cell types remains to be elucidated, however.
Because somatostatin analogs inhibit the secretion of insulin, impaired glucose tolerance was observed after the acute administration of octreotide (31) . Recently we observed similar glucose responses to the acute administration of SOM230 in vivo (32) . However, SOM230 did not modify insulin secretion, suggesting another mechanism of action. The inhibitory effect of octreotide on insulin secretion is short-lived, and clinically important effects on carbohydrate metabolism during long-term therapy are not observed (33) . Although the acute rise in glucose levels after SOM230 injection requires further attention, preclinical studies in cynomolgus monkeys showed that insulin, glucagon, and glucose levels remained unchanged after 7 d of high-dose infusion with SOM230 (13) . In addition, 126 d treatment of rats with pharmacological doses of SOM230 did not modify plasma glucose levels (12) . These data suggest that SOM230 is well tolerated in rats and monkeys with regard to glucose homeostasis.
In conclusion, the novel universal SRIF analog SOM230 is a potent inhibitor of GH and PRL secretion in GH-secreting pituitary adenomas. The higher number of cultures responding to SOM230, compared with OCT, suggests that SOM230 has the potential to increase the number of patients controlled biochemically, both via sst 2 and sst 5 . In addition, SOM230 is more potent in its inhibitory effect on PRL secretion in mixed GH/PRL-secreting pituitary adenomas. In prolactinoma cultures, sst 5 receptors mediate the potent inhibitory effects of SOM230 on PRL secretion. Because the majority of patients with prolactinomas are successfully treated using DA agonists, there may be a role for SOM230 in the treatment of prolactinoma patients, which are intolerant to DA agonists.
